I agree, I think earnings will be bullish. I am also looking to see the O/S dilution trend decreasing and to see a better net working capital.
Keep in mind FDA regulation risk currently priced in is overstated with the new Trump Administration reducing regulation on small business including FDA regulations.
I think we will be back to .02s here in the next several sessions.